New prospects for drug treatment of chronic cerebral ischemia from the standpoint of neuroinflammation

The high prevalence of stroke worldwide requires a revision the modern doctrine management patients with cerebrovascular disease. It is obvious that only aggressive modification risk factors for vascular pathology does not guarantee prevention acute accident, which an intermediate or final stage In this regard, use neuroprotectors, including vinpocetine, can increase tolerance brain tissue to hypoxia. Vinpocetine, derivative alkaloid vincamine, inhibiting phosphodiesterase and voltage-dependent Na+- channels widely used in many countries treatment diseases, chronic cerebral ischemia. Recent studies have identified number new therapeutic effects stimulation neuroplasticity via brain-derived neurotrophic factor inhibition neuroinflammation. latter mechanism mediated by effect on NF-kB suppresses expression NF-kBdependent pro-inflammatory molecules prevents formation NLRP3 inflammasome. New data allow reconsider place vinpocetine disorders, recommend its wide range